Improving treatment for atrial fibrillation using light and computer modeling
Optimizing AF ablation by a novel optogenetics and computational approach
This study is exploring a new way to treat atrial fibrillation (AF) by using light to control heart cells and computer models to better understand the condition, with the goal of finding safer and more effective treatments for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10676183 on NIH RePORTER |
What this research studies
This research focuses on enhancing the treatment of atrial fibrillation (AF), a common heart condition that can lead to serious complications like stroke and heart failure. The approach combines optogenetics, which uses light to control cells, with advanced computer simulations to better understand and manage AF. By targeting the specific areas of the heart affected by this condition, the research aims to develop more effective treatment strategies that go beyond current methods. Patients may benefit from improved outcomes and reduced risks associated with AF.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with atrial fibrillation, particularly those who have not responded well to existing treatments.
Not a fit: Patients with other types of arrhythmias or those who are not diagnosed with atrial fibrillation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for atrial fibrillation, improving patient quality of life and reducing the risk of serious complications.
How similar studies have performed: Previous research has shown promise in using optogenetics and computational modeling for cardiac conditions, suggesting potential for success in this novel approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Akar, Fadi Gabriel — Yale University
- Study coordinator: Akar, Fadi Gabriel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.